| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/400 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CALT; CEN2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CETN2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CETN2抗体的参考文献及其摘要内容：
---
1. **文献名称**: "Centrin-2 (CETN2) overexpression promotes genome instability in human tumor cells"
**作者**: Salisbury, J.L. et al.
**摘要**: 该研究利用CETN2抗体通过免疫荧光和Western blot分析，发现CETN2过表达导致肿瘤细胞基因组不稳定，可能与中心体异常扩增和染色体错误分离相关。
---
2. **文献名称**: "DNA damage-induced phosphorylation of centrin-2 (CETN2) by ATM/ATR kinases regulates DNA repair"
**作者**: D'Angiolella, V. et al.
**摘要**: 研究通过CETN2抗体结合质谱分析，揭示CETN2在DNA损伤后被ATM/ATR激酶磷酸化，调控XRCC5蛋白复合体组装，影响非同源末端连接(NHEJ)修复效率。
---
3. **文献名称**: "Centrin-2 (CETN2) interacts with BRCA1 and modulates its transcriptional activity in breast cancer cells"
**作者**: Li, S. et al.
**摘要**: 通过免疫共沉淀(Co-IP)和CETN2抗体的应用，研究发现CETN2与BRCA1结合，影响BRCA1在DNA修复和细胞周期检查点中的功能，可能参与乳腺癌发生机制。
---
(注：上述文献信息为模拟示例，实际文献需通过学术数据库检索确认。)
The CETN2 antibody targets Centrin-2 (CETN2), a small calcium-binding protein belonging to the centrin family, which is evolutionarily conserved across eukaryotes. CETN2 is primarily localized to centrosomes, basal bodies, and ciliary structures, playing critical roles in centriole duplication, centrosome assembly, and ciliogenesis. It interacts with proteins like XRCC5 (Ku80) to participate in DNA damage repair processes, linking centrosomal functions to genomic stability. CETN2 is also implicated in regulating cell cycle progression, particularly during the G1/S transition and mitotic exit.
Antibodies against CETN2 are widely used in research to study centrosome dynamics, ciliary dysfunction, and mechanisms underlying diseases such as ciliopathies, cancer, and infertility. These antibodies enable techniques like immunofluorescence microscopy to visualize centrosome structure, Western blotting to assess protein expression levels, and immunoprecipitation to explore protein interaction networks. CETN2 expression is often elevated in certain cancers, making it a potential biomarker for tumor progression.
Validation of CETN2 antibodies typically involves knockout cell lines or siRNA-mediated knockdown to confirm specificity. Cross-reactivity with other centrin isoforms (e.g., CETN1 or CETN3) is a consideration during experimental design. Studies using CETN2 antibodies have advanced understanding of how centrosomal abnormalities contribute to microcephaly, retinal degeneration, and other developmental disorders, underscoring its biomedical relevance.
×
